By Colin Kellaher
Mersana Therapeutics shares rose sharply after the biopharmaceutical company won a second Food and Drug Administration fast-track designation for a proposed treatment for breast cancer and reported positive early stage study results for the drug.
Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or HER2-negative disease, including triple-negative breast cancer, who have received a prior topoisomerase-1 inhibitor antibody-drug conjugate.
Mersana shares, which closed Wednesday at $1.30, were recently up 22% at $1.59 in premarket trading.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
The agency previously granted fast-track designation to XMT-1660 for the treatment of adults with advanced or metastatic recurrent triple-negative breast cancer.
Mersana also reported positive initial data from the dose-escalation and backfill cohorts of a Phase 1 study of XMT-1660.
The Cambridge, Mass., company said it saw promising clinical activity in patients with triple-negative breast cancer previously treated with topoisomerase-1 inhibitor ADCs, adding that the drug was generally well tolerated.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 10, 2025 06:45 ET (11:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.